A Synthetic Interaction Screen Identifies Factors Selectively Required for Proliferation and TERT Transcription in p53-Deficient Human Cancer Cells

Howard Hughes Medical Institute, Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
PLoS Genetics (Impact Factor: 7.53). 12/2012; 8(12):e1003151. DOI: 10.1371/journal.pgen.1003151
Source: PubMed


Numerous genetic and epigenetic alterations render cancer cells selectively dependent on specific genes and regulatory pathways, and represent potential vulnerabilities that can be therapeutically exploited. Here we describe an RNA interference (RNAi)-based synthetic interaction screen to identify genes preferentially required for proliferation of p53-deficient (p53-) human cancer cells. We find that compared to p53-competent (p53+) human cancer cell lines, diverse p53- human cancer cell lines are preferentially sensitive to loss of the transcription factor ETV1 and the DNA damage kinase ATR. In p53- cells, RNAi-mediated knockdown of ETV1 or ATR results in decreased expression of the telomerase catalytic subunit TERT leading to growth arrest, which can be reversed by ectopic TERT expression. Chromatin immunoprecipitation analysis reveals that ETV1 binds to a region downstream of the TERT transcriptional start-site in p53- but not p53+ cells. We find that the role of ATR is to phosphorylate and thereby stabilize ETV1. Our collective results identify a regulatory pathway involving ETV1, ATR, and TERT that is preferentially important for proliferation of diverse p53- cancer cells.

Download full-text


Available from: Lihua Julie Zhu
  • Source
    • "Some cancers show p53 deficient and vice versa. ChIP can be used to analyze p53 (Xie, et al., 2012). From this research, p53 deficient and competent show different characteristic. "

    Full-text · Article · Jan 2016
  • Source
    • "The development of shRNA-based libraries and the advancement of next generation sequencing platforms have enabled individuals to perform genome-wide synthetic lethal screens [98,99,100]. For example, Xie et al. [101] recently performed a whole genome screen to identify synthetic lethal interactors of TP53. Isogenic wild-type and TP53-deficient colorectal cancer cells (HCT116) were transduced with an shRNA library containing approximately 60,000 clones. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer is a leading cause of death throughout the World. A limitation of many current chemotherapeutic approaches is that their cytotoxic effects are not restricted to cancer cells, and adverse side effects can occur within normal tissues. Consequently, novel strategies are urgently needed to better target cancer cells. As we approach the era of personalized medicine, targeting the specific molecular defect(s) within a given patient's tumor will become a more effective treatment strategy than traditional approaches that often target a given cancer type or sub-type. Synthetic genetic interactions are now being examined for their therapeutic potential and are designed to target the specific genetic and epigenetic phenomena associated with tumor formation, and thus are predicted to be highly selective. In general, two complementary approaches have been employed, including synthetic lethality and synthetic dosage lethality, to target aberrant expression and/or function associated with tumor suppressor genes and oncogenes, respectively. Here we discuss the concepts of synthetic lethality and synthetic dosage lethality, and explain three general experimental approaches designed to identify novel genetic interactors. We present examples and discuss the merits and caveats of each approach. Finally, we provide insight into the subsequent pre-clinical work required to validate novel candidate drug targets.
    Full-text · Article · Sep 2013 · Cancers
  • Source

    Full-text · Dataset · Aug 2013
Show more